Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug ...

Adverse events leading to trial discontinuation were 2.6% for the semaglutide group and 3.3% for the placebo group. 1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH.

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

VCU-led research highlights semaglutide’s potential for treating fatty liver disease Provided by GlobeNewswire Apr 30, 2025, 10:09:48 PM ...

MASH Approval Could Help Change the Narrative Around Semaglutide With these results, Novo plans to file for regulatory approval of semaglutide to treat MASH in the first half of 2025.

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...